BofA analyst Jason Gerberry raised the firm’s price target on Alkermes (ALKS) to $36 from $34 and keeps a Neutral rating on the shares. The firm adjusted several targets in conjunction with its Q1 preview for its large-cap pharma and small-to-mid cap biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS: